Evidence map›Paper›PMID 42262688›Full record

ArticleInternational journal of clinical oncology2026

Geriatric nutritional risk index for the prediction of venous thrombotic events in multiple myeloma.

Kazuhito Suzuki, Tadahiro Gunji, Riku Nagao, Masaharu Kawashima, Hideki Uryu, Mamiko Momoki, Hiroto Ishii, Ryoko Fukushima, Mitsuji Katori, Hiroki Yokoyama and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kazuhito SuzukiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan. kaz-suzuki@jikei.ac.jp.ORCID http://orcid.org/0000-0002-0300-378X
Tadahiro GunjiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Riku NagaoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Masaharu KawashimaDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Hideki UryuDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Mamiko MomokiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Hiroto IshiiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Ryoko FukushimaDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Mitsuji KatoriDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Hiroki YokoyamaDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Atsushi KatsubeDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Takeshi SaitoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Kaichi NishiwakiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.
Shingo YanoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-0003, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe geriatric nutritional risk index (GNRI) is an indicator of nutritional status and predicts overall survival (OS) in patients with myeloma. A low GNRI score indicates malnutrition associated with venous thromboembolism (VTE). This retrospective study aimed to investigate the clinical relevance of GNRI in VTE in patients with myeloma.

methodsWe reviewed the medical records of 357 patients who were newly diagnosed with myeloma and treated with proteasome inhibitors and/or immunomodulatory drugs. VTE included deep vein thrombosis and pulmonary embolism diagnosed using imaging studies. The cutoff value for the GNRI was 92, according to previous studies.

resultsThe median age of the patients was 71 years. The 1-year cumulative incidence of VTE was 4.9%. The median time from diagnosis to VTE was 2.8 months (range, 0.1-86.8 months). A low GNRI was associated with a high incidence of VTE (hazard ratio [HR], 3.885; P < 0.001). During a median follow-up of 37.8 months, OS was significantly shorter in patients with low GNRI scores and those who developed VTE within 1 year than in those with high GNRI scores who did not develop VTE (log-rank test, P < 0.001 and P = 0.047, respectively). Multivariate analysis revealed that low GNRI (HR, 1.562; P = 0.050) and VTE within 1 year (HR, 3.470; P = 0.017) were associated with shorter OS.

conclusionA low GNRI score is associated with a high incidence of VTE in patients with myeloma. The GNRI and VTE within 1 year were associated with mortality.

Indexed as

Geriatric AssessmentMultiple MyelomaNutrition AssessmentVenous ThrombosisAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedNutritional StatusPrognosisRetrospective StudiesRisk FactorsGeriatric nutritional risk indexMyelomaSurvival timeVenous thrombotic events

Identifiers

PMID42262688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.